CH
BIO icon

Canton Hathaway’s Bio-Rad Laboratories Class A BIO Stock Holding History

Canton Hathaway’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-217
Closed -$112K – 259
2020
Q3 		$112K Buy
+217
New +$110K 0.05% 152

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Canton Hathaway's BIO Position: Q4 2020 in Review

Canton Hathaway sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2020, closing a stake of 217 shares — an estimated $112K sold.

Canton Hathaway first reported a position in BIO in Q3 2020 and held it in 1 quarter. The position peaked at $112K in Q3 2020. 491 funds tracked by Wall St. Rank hold BIO as of Q4 2020.

  • Canton Hathaway reported no remaining Bio-Rad Laboratories Class A position as of Q4 2020 after selling out during the quarter.
  • Canton Hathaway sold 217 Bio-Rad Laboratories Class A shares in Q4 2020, an estimated $112K.
  • Canton Hathaway first reported a position in Bio-Rad Laboratories Class A in Q3 2020 and held it in 1 quarter.
  • Canton Hathaway's Bio-Rad Laboratories Class A position peaked at $112K in Q3 2020.
  • 491 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2020.

Based on Canton Hathaway's 13F filing for Q4 2020, filed 3 Feb 2021.